Clinical Trials Browser

Withdrawn × Adjuvants, Immunologic × Clear all

Multiple Myeloma

NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma, Glioma

NCT00024115 2015-04-28

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00052403 2014-01-16

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00017160 2013-06-27

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma

Phase 2 Withdrawn

Sarcoma

Clinical Trials

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma